Gastric cancer (GC) is a leading cause of global mortality but also a cancer whose footprint
is highly unequal. This review aims to define global disease epidemiology, critically …

Despite the substantial burden of gastric cancer worldwide, population strategies for primary
prevention have not been introduced in any country. Recognizing the causal role of …

In dieser Leitlinie sind eingetragene Warenzeichen (geschützte Warennamen) nicht
besonders kenntlich gemacht. Es kann also aus dem Fehlen eines entsprechenden …

Objectives: We aimed to assess a serological biopsy using five stomach-specific circulating
biomarkers—pepsinogen I (PGI), PGII, PGI/II ratio, anti-Helicobacter pylori (H. pylori) …

Background To identify high-risk groups for gastric cancer in presumptively healthy
populations, several studies have investigated the predictive ability of the pepsinogen test …

Auch wenn nach internationalen, populationsbasierten Studien die Prävalenz der
Helicobacter pylori (H. pylori)-Infektion in den letzten Jahren abgenommen hat, bleibt etwa …

Serum pepsinogen assay (sPGA), which reveals serum pepsinogen (PG) I concentration
and the PG I/PG II ratio, is a non-invasive test for predicting chronic atrophic gastritis (CAG) …

Endoscopic findings of the background gastric mucosa are important in the Helicobacter
pylori-seroprevalent population. It is strongly correlated not only with the risk of gastric …

Background Non-invasive tools for gastric cancer screening and diagnosis are lacking.
Serological testing with the detection of pepsinogen 1 (PG1), pepsinogen 2 (PG2) and …

Background: There is little information regarding whether the combination of Helicobacter
pylori (H. pylori) antibody and serum pepsinogen (sPG), which is a marker of the degree of …